← Back to Screener
Neuronetics, Inc. Common Stock (STIM)
Price$1.29
Value ScoreB
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-21.35%
Price vs S&P 500 (4W)-22.04%
VGM Score57.80
Market Capitalization$89.77M
All Metrics
Book Value / Share (Quarterly)$0.19
P/TBV (Annual)22.35x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)31.76%
Cash Flow / Share (Quarterly)$-0.20
Price vs S&P 500 (YTD)-14.68%
Gross Margin (TTM)47.96%
Net Profit Margin (TTM)-24.48%
EPS (TTM)$-0.55
10-Day Avg Trading Volume2.14M
EPS Excl Extra (TTM)$-0.55
Revenue Growth (5Y)24.81%
EPS (Annual)$-0.59
ROI (Annual)-44.22%
Gross Margin (Annual)48.48%
Net Profit Margin (5Y Avg)-48.04%
Cash / Share (Quarterly)$0.19
Revenue Growth QoQ (YoY)7.75%
ROA (Last FY)-27.55%
Revenue Growth TTM (YoY)69.52%
EBITD / Share (TTM)$-0.39
ROE (5Y Avg)-104.40%
Operating Margin (TTM)-19.76%
Cash Flow / Share (Annual)$-0.31
P/B Ratio6.77x
P/B Ratio (Quarterly)7.61x
Net Income / Employee (Annual)$-59,300
EV / Revenue (TTM)0.91x
Net Interest Coverage (TTM)-3.65x
ROA (TTM)-27.13%
EPS Incl Extra (Annual)$-0.59
Current Ratio (Annual)2.02x
Quick Ratio (Quarterly)1.25x
3-Month Avg Trading Volume2.43M
52-Week Price Return-66.32%
Revenue / Employee (TTM)$230,400
Tangible BV / Share (Quarterly)$0.06
P/S Ratio (Annual)0.60x
Asset Turnover (Annual)1.05x
52-Week High$4.85
Operating Margin (5Y Avg)-43.93%
EPS Excl Extra (Annual)$-0.59
CapEx CAGR (5Y)1.87%
26-Week Price Return-13.42%
Quick Ratio (Annual)1.68x
13-Week Price Return-8.51%
Total Debt / Equity (Annual)2.94x
Current Ratio (Quarterly)1.67x
Enterprise Value$137.85M
Revenue / Share Growth (5Y)-2.85%
Asset Turnover (TTM)1.11x
Book Value / Share Growth (5Y)-24.65%
Revenue / Employee (Annual)$226,700
Inventory Turnover (Annual)17.92x
Pretax Margin (Annual)-26.24%
Cash / Share (Annual)$0.41
3-Month Return Std Dev129.91%
Gross Margin (5Y Avg)69.69%
Net Income / Employee (TTM)$-56,400
ROE (Last FY)-174.27%
Net Interest Coverage (Annual)-3.25x
EPS Basic Excl Extra (Annual)$-0.59
Receivables Turnover (TTM)7.22x
Total Debt / Equity (Quarterly)4.62x
EPS Incl Extra (TTM)$-0.55
Receivables Turnover (Annual)7.49x
ROI (TTM)-43.86%
P/S Ratio (TTM)0.59x
Pretax Margin (5Y Avg)-48.06%
Revenue / Share (Annual)$2.26
Tangible BV / Share (Annual)$0.06
Price vs S&P 500 (52W)-90.68%
Year-to-Date Return-6.52%
5-Day Price Return-22.75%
EPS Normalized (Annual)$-0.59
ROA (5Y Avg)-27.70%
Net Profit Margin (Annual)-26.15%
Month-to-Date Return-16.23%
Cash Flow / Share (TTM)$-1.10
EBITD / Share (Annual)$-0.42
Operating Margin (Annual)-21.08%
LT Debt / Equity (Annual)2.94x
ROI (5Y Avg)-39.01%
LT Debt / Equity (Quarterly)4.62x
EPS Basic Excl Extra (TTM)$-0.55
P/TBV (Quarterly)22.35x
P/B Ratio (Annual)4.22x
Inventory Turnover (TTM)17.97x
Pretax Margin (TTM)-24.55%
Book Value / Share (Annual)$0.32
Price vs S&P 500 (13W)-16.77%
Beta1.09x
Revenue / Share (TTM)$2.18
ROE (TTM)-164.68%
52-Week Low$0.80
vGradeB
gGradeB
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.15est. -0.18
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.11
4.11
4.11
4.11
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
STIMNeuronetics, Inc. Common Stock | B | B | D | $1.29 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Neuronetics Inc is a medical device company specializing in transcranial magnetic stimulation (TMS) therapy for psychiatric disorders. Its flagship product, the NeuroStar Advanced Therapy System, is a non-invasive, office-based treatment that uses MRI-strength magnetic fields to stimulate brain regions associated with mood regulation. NeuroStar is approved to treat major depressive disorder (MDD) and offers an alternative to conventional psychiatric therapies that may have significant side effects or efficacy limitations.